Vyome Holdings (HIND) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Vyome Holdings stock $1.04, price $1.53, that is 32.0% below the price, quality 22 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Vyome Holdings
HIND · USExpensive (fair value 32% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range $1.53 – $1,000,000 · fair‑value band $0.7800 – $1.30 · the $1.53 price screens above the $1.04 fair value. As of Nov 15, 2026.
Every Wednesday you see whether Vyome is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Show moreShow less
The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis.
It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne.
In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products.
The company is based in Cambridge, Massachusetts.
Stock analysis
Vyome Holdings (HIND) currently trades at $1.53, while our estimate is $1.04, 32% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $0.7800 (bear) to $1.30 (bull), the price of $1.53 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Vyome Holdings reported revenue of $320K in FY2025 versus $13.6M in FY2021, a compound −60.8%/yr. Reported net income was −$10.3M in FY2025.
Key figures
Market cap $10.7M Micro · P/E ratio 0.9 · P/S ratio 72.4 · EPS (TTM) $1.78 · Return on equity −74.8% · Return on assets (EBIT) −138% (5-year average) · Operating margin −2,854% · Revenue (TTM) $153K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 73% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −32%, HIND screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Earlier news
- Vyome appoints new CFO
- Vyome Holdings, Inc. reports FY results
- Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
- Vyome Holdings expands at-the-market offering and appoints new auditor
Compare Vyome Holdings with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs HIND |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs HIND |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs HIND |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs HIND |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs HIND |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs HIND |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs HIND |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs HIND |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs HIND |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs HIND |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Vyome Holdings (HIND) overvalued or undervalued?
What is the fair value of HIND?
What is the quality score of HIND?
What is the price target for Vyome Holdings (HIND)?
What is the Vyome Holdings stock forecast for 2026?
What is the revenue of Vyome Holdings (HIND)?
What is the intrinsic value of Vyome Holdings (HIND)?
Is Vyome Holdings stock overvalued or undervalued in 2026?
Is fair value the same as the market price of HIND?
How much is Vyome Holdings worth?
What do the bullish and bearish scenarios say about HIND?
What is the P/E ratio of HIND?
How solid is the balance sheet of Vyome Holdings (HIND)?
How far is HIND from its 52-week high?
Which stocks are comparable to Vyome Holdings?
Is Vyome Holdings stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Vyome Holdings (HIND)?
What should I pay attention to with Vyome Holdings right now?
Key figures of Vyome Holdings
How large is the market capitalisation of Vyome Holdings (HIND)?
What is the P/S ratio of Vyome Holdings (HIND)?
What are the earnings per share of Vyome Holdings (HIND)?
What is the return on equity of Vyome Holdings (HIND)?
What is the EBIT return on assets of Vyome Holdings (HIND)?
What is the operating margin of Vyome Holdings (HIND)?
How fast is revenue growing at Vyome Holdings (HIND)?
How much free cash flow does Vyome Holdings (HIND) generate?
How much net cash does Vyome Holdings (HIND) hold?
Watch Vyome Holdings in the live analysis
One click puts Vyome Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.